Skip to Main Content

Paper Details

Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer.
J Clin Invest
19
2021
CHD1, CHD1-deleted, Cancer, ERG, ERG+ and SPOP-mutant subtypes, PCa, PTEN, SPOP, SPOP-mutant, SPOP-mutant tumors, Tumor, Tumor subtype, human, patients, primary prostate cancer, prostate cancer, transcriptional, tumor, tumor lineage, tumor lineage models
Author NameAffiliation
Davide PrandiFondazione Bruno Kessler (FBK)
Davide PrandiFondazione Bruno Kessler (FBK)
Yang Liu
Robert Jeffrey KarnesMayo Clinic
Bruce J TrockJohns Hopkins University
Eric A KleinGlickman Urological and Kidney Institute, Cleveland Clinic
Robert B DenSidney Kimmel Medical College at Thomas Jefferson University
Francesca DemichelisUniversity of Trento
Francesca DemichelisUniversity of Trento
Elai Davicioni
Andrea SbonerSandra and Edward Meyer Cancer Center and.
Andrea Sboner
Andrea SbonerEnglander Institute for Precision Medicine of Weill Cornell Medicine and NewYork-Presbyterian Hospital
Andrea SbonerHRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medical College
Andrea SbonerSandra and Edward Meyer Cancer Center and.
Andrea SbonerHRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medical College
Andrea SbonerEnglander Institute for Precision Medicine of Weill Cornell Medicine and NewYork-Presbyterian Hospital
Andrea Sboner
Christopher E BarbieriSandra and Edward Meyer Cancer Center and.
Christopher E Barbieri
Christopher E BarbieriEnglander Institute for Precision Medicine of Weill Cornell Medicine and NewYork-Presbyterian Hospital
Christopher E BarbieriSandra and Edward Meyer Cancer Center and.
Christopher E Barbieri
Christopher E BarbieriEnglander Institute for Precision Medicine of Weill Cornell Medicine and NewYork-Presbyterian Hospital
  • 1 - 24

Datasets

Release 1.2